Clinical trials: FLU
Influenza
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
The purpose of the present study is to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with vaccine GSK2340272A when co-administered with GSK Biologicals' Fluarix™ vaccine either at the time of first…
- Trial name
- NCT00968890
- Testing
- Pandemrix (Influenza vaccine GSK2340272A), Fluarix™
- Where
- 2 sites in Sweden
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386113
- Testing
- Fluarix and adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of Quadrivalent Influenza Vaccine Among Children
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1), and the investigational TIV containing the…
- Trial name
- NCT01240746
- Testing
- Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative
- Where
- 67 sites in United States
- Volunteers
- 4,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pregnancy, Influenza
A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy
The primary research question of this study is: Does the pharmacokinetics of oseltamivir after a single oral dose differ between the pregnant and non-pregnant women?
- Trial name
- NCT00873886
- Testing
- Oseltamivir (Tamiflu), Blood Draws
- Where
- United States
- Sponsor
- University of Pittsburgh
Influenza
Rapid Vaccination of Hard-To-Reach Populations
The purpose of this study is to develop and determine the effectiveness of a multi-level community participatory intervention designed to rapidly immunize hard-to-reach populations, including substance users, within disadvantaged…
- Trial name
- NCT00155974
- Testing
- Community-based vaccine outreach intervention
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- The New York Academy of Medicine
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as short-term prophylaxis against pandemic influenza infection in people who have close familial contact with the disease.
- Trial name
- PIPET C (NCT00640874)
- Where
- 8 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kirby Institute
Immunosuppression
Influenza Vaccination in Immunocompromized Patients
Evaluation of the immunogenicity and reactogenicity of two different formulations of commercially avail-able influenza vaccines in 4 different groups of immunocompromized outpatients (HIV positive patients, patients suffering…
- Trial name
- NCT00783380
- Testing
- Virosomal influenza vaccine, Subunit influenza vaccine
- Where
- 3 sites in Switzerland
- Volunteers
- 304 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Healthy
Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route
Background: It is well established that live attenuated organisms can be highly effective vaccines, immune responses elicited can often be of greater magnitude and of longer duration than those produced by non-living antigens and…
- Trial name
- NCT01488188
- Testing
- Influenza vaccine
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Clinical Trial of KT07 Capsule in the U.S.A
The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in…
- Trial name
- NCT02867358
- Testing
- KT07 Capsule
- Where
- 81 sites in United States
- Volunteers
- 391 people
- Sponsor
- Yiling Pharmaceutical Inc.
Influenza, Human
Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
An open label, non-comparative bridging study to evaluate the safety of GCFLU® (seasonal influenza vaccine) administered intramuscularly in healthy Vietnamese volunteer aged from 3 years old
- Trial name
- NCT02723812
- Testing
- GCFLU® Influenza vaccine (Split virion, Inactivated)
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Pandemic Influenza, Influenza A Virus Infection
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity…
- Conditions
- Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections
- Trial name
- NCT00457509
- Testing
- A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, A/H5N1 inactivated, split-virion influenza vaccine
- Where
- 3 sites in Belgium
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
The purpose of this study was to evaluate the antibody response to each of the four influenza vaccine strains included in the study vaccine, as measured by hemagglutination inhibition (HAI) at 4 weeks after the last dose of the…
- Trial name
- NCT04101435
- Testing
- AdimFlu-S (QIS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Human Influenza
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine.
- Trial name
- NCT01096225
- Testing
- split-virion, H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Safety Issues
Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population
This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population
- Trial name
- NCT03336593
- Testing
- Quadrivalent Influenza Vaccine, Trivalent Influenza Vaccine
- Where
- 3 sites in Indonesia
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Influenza
TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B
Each winter, viruses belonging to two kinds of influenza A ("A/H1N1" \& "A/H3N2") and two kinds of influenza B ("B/Yamagata" \& "B/Victoria") can cause illness.
- Trial name
- TITRE II (NCT01067404)
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 3 sites in Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- British Columbia Centre for Disease Control
Influenza A Virus Infection
Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells
Rationale: Classical antiviral therapies target viral proteins and are consequently subject to resistance. To counteract this limitation, alternative strategies have been developed that target cellular factors.
- Trial name
- FLUMED (NCT01546506)
- Testing
- Gutron® treatment
- Where
- 39 sites in France
- Volunteers
- 79 people
- Sponsor
- Hospices Civils de Lyon
Influenza
Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above
Vaccination is currently the most effective mean of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00345904
- Testing
- Fluarix
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00964158
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.